Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company"), and Wex Pharmaceuticals, Inc. ("WEX"), a wholly owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc. ("CKLS"), today announced that Virios has entered into a definitive share exchange agreement with Sealbond Limited, an indirect parent of Wex, pursuant to which the companies will combine in an all-stock transaction (the "Combination").

The combined company's new name will be Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("Dogwood") and it will be focused on the clinical development of three assets: Halneuron, currently in Phase 2b development for chemotherapy-induced neuropathic pain ("CINP"); IMC-1, poised for Phase...